Lotus Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Zhong Yi Liu

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	19.5yrs
CEO ownership	n/a
Management average tenure	15.5yrs
Board average tenure	15.3yrs

Recent management updates

No updates

Recent updates

CEO

Zhong Yi Liu (64 yo)

19.5yrs

Tenure

US$191,000

Compensation

Dr. Zhong Yi Liu is the Founder and has been Chairman of the Board, President and Chief Executive Officer of Lotus Pharmaceuticals, Inc. since September 28, 2006. Dr. Liu is the Founder of Lotus Pharmaceut...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhong Yi Liu	Founder	19.5yrs	US$191.00k	no data
Yan Zeng	Chief Financial Officer and Principal Accounting Officer	15.5yrs	no data	no data
Xing Shen	Vice President of Corporate Development	15.5yrs	no data	no data

15.5yrs

Average Tenure

56yo

Average Age

Experienced Management: LTUS's management team is seasoned and experienced (15.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhong Yi Liu	Founder	19.5yrs	US$191.00k	no data
Zhaohui Li	Director	15.3yrs	no data	no data
Lijun Fan	Director	15.3yrs	no data	no data
Jun Lu	Director	15.3yrs	no data	no data

15.3yrs

Average Tenure

55yo

Average Age

Experienced Board: LTUS's board of directors are seasoned and experienced ( 15.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/12 14:21
End of Day Share Price	2026/02/25 00:00
Earnings	2011/09/30
Annual Earnings	2010/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lotus Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.